• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Vaccines / HPV / Cervical cancer incidence can increase despite HPV vaccination

Cervical cancer incidence can increase despite HPV vaccination

January 17, 2011 By admin Leave a Comment

By:  Diane M. Harper, et al.

September 2010

We read with interest the conclusion that Chris Bauch and colleagues1 presented, indicating that the incidence of cervical cancer would be very unlikely to increase as a result of human papillomavirus (HPV) vaccination. The investigators conclude that screening coverage in a population is unlikely to decline to levels that would be necessary to lead to an increase cervical cancer incidence—this being an 80% decrease in screening with 30% vaccine coverage. We refute their conclusions and present data from the UK and Finland that show that screening less than 20% of young women resulted in a substantial increase in cervical cancer incidence in an unvaccinated female population. With increasing background exposure to high-risk HPV, the incidence of cervical cancer did not decrease in the UK until at least 70% of the population were appropriately screened.2, 3 Likewise, when less than 70% of the population is screened, only individual benefits result and the population incidence of cervical cancer is not reduced.

Finland adopted organised cervical cancer screening in the early 1960s. For the first decade of organised screening, incidence was 14–16 per 100 000 woman-years,4 effectively finding the prevalent cancer cases in the previously unscreened population. By 1970, organised screening coverage had reached at least 70% of the target population, and the incidence of invasive cervical cancer dropped sharply by 75% over the next 20 years. Incidence rose again to an overall level of 4 per 100 000 woman-years over the next 10 years.5 Why did this happen?

In 1985, when cervical cancer incidence was still quickly declining, the actual incidence corresponded to predictions that were based on previous decreases;6 however, for every subsequent year, the rate of cervical cancer was higher than predicted for women aged 30–39 years4, 5—the peak age group for cervical cancer. In Finland, every year the rate continued to increase by 3 per 100 000 woman-years until it was more than four times higher than the expected rate per 1 million person-years for 30–39 year old women (figure 1); a real step backwards for cervical cancer prevention in the population. In contrast, over the same period, cancer rates for women over 50 years old continued to decrease as expected because over 70% of these women still actively attended screening. Reasons for increases in cervical cancer in younger women were a willful lack of screening and rapid increases in HPV16 incidence and prevalence.7 The Finnish Mass Screening Registry5 reported that less than 60% of women less than 40 years of age accepted the invitation to be screened in 2003, and only 20% of the women 25–30 years of age participated in the screening programme (figure 2). Assuming low vaccine coverage (30%), which gains no herd benefit,8 these data fulfil the thresholds that Bauch and colleagues1 defined for cervical cancers to increase after HPV vaccination. Willful lack of screening participation is already occurring in our youngest women, who have the lowest awareness of the magnitude of the morbidity and mortality of cervical cancer. An increase in cervical cancer can be seen as soon as 5 years after a willful decrease of participation in screening programmes and an ongoing high-risk HPV epidemic.

 

 Opens large image

Figure 1

Sentinel warning

By 2005, the incidence of cervical cancer had increased more than four times over the rate predicted by historical screening patterns for 30–39 year old Finnish women per 1 million person-years.7

View Large Image | View Hi-Res Image | Download PowerPoint Slide

 

 Opens large image

Figure 2

Coverage of the 2003 Finnish cervical cancer screening programme in 2003

The dashed line represents the 70% minimum coverage rate that is needed to gain a population benefit from organised cervical cancer screening programmes.4, 5

View Large Image | View Hi-Res Image | Download PowerPoint Slide

Organised HPV vaccination combined with screening could potentially prevent most cervical cancer.

Read the full article: http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(10)70182-1/fulltext

Related

Filed Under: HPV, Vaccines Tagged With: HPV, HPV infections, vaccination, vaccine

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Ashleigh from Liverpool

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

Gardasil Cervarix HPV Vaccine Survey

Have you or your child been given a genetically modified vaccine?

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in